我们进行了全面的系统评价,以确定药物相关的眼眶炎症并表征其临床放射学特征。我们回顾了描述药物相关眼眶炎症的英语文章(即,眼眶肌炎,泪腺炎和眼眶脂肪)出版至2023年6月。眼内结构或单独的眼球的孤立炎症(即葡萄膜炎),巩膜炎,视神经炎和周围神经炎)被排除。在药物相关的眼眶炎症中,眼外肌优先受到影响,单独发生或与其他眼眶和/或眼内结构组合。临床放射学表现可能是非特异性的;然而,某些药物可以根据系统性前驱症状的存在来区分,偏侧性,相关眼内炎症,以及涉及某些轨道结构的倾向。快速识别,停止挑衅药物,和全身性皮质类固醇治疗(如果合适)通常实现良好的视觉预后。随着新药被临床医生采用,将进一步描述罕见的不良反应。药物相关眼眶炎症是眼眶炎性疾病的重要诊断考虑因素。仔细的用药史和临床评估可能会揭示,允许及时停止违规代理人并启动适当的管理。
We performed a comprehensive systematic
review to identify medication-associated orbital inflammation and to characterize its clinico-radiological features. We reviewed English-language articles describing medication-associated orbital inflammation (i.e., orbital myositis, dacryoadenitis and orbital fat) published to June, 2023. Isolated inflammation of the intraocular structures or globe alone (i.e. uveitis, scleritis, optic neuritis and perineuritis) were excluded. In medication-associated orbital inflammation, the extraocular muscles are preferentially affected, occurring in isolation or in combination with other orbital and/or intraocular structures. Clinico-radiological manifestations may be non-specific; however, certain medications may be distinguished according to the presence of systemic prodrome, laterality, associated intraocular inflammation, and predisposition to involve certain orbital structures. Rapid identification, discontinuation of the provoking medication, and systemic corticosteroid therapy (if appropriate) typically achieves a favorable visual prognosis. As new medications become adopted by clinicians, rare adverse effects will be further delineated.Medication-associated orbital inflammation is an important diagnostic consideration in orbital inflammatory disease. A careful medication history and clinical assessment may be revealing, permitting timely discontinuation of the offending agent and initiation of appropriate management.